1Schellekens GA,Visser H,de Jong BA,et al.The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.Arthritis Rheum,2000,43:155.
2Aletaha D,Neogi T,Silman AJ,et al.2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Ann Rheum Dis,2010,69:1580.
3Gaujoux-Viala C,Smolen JS,Landewé R,et al.Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.Ann Rheum Dis,2010,69:1004.
4Schipper LG,van Hulst LT,Grol R,et al.Meta-analysis of tight control strategies in rheumatoid arthritis:protocolized treatment has additional value with respect to the clinical outcome.Rheumatology (Oxford),2010 Jul 29.
5Teh CL,Wong JS.Impact of tight control strategy on rheumatoid arthritis in Sarawak.Clin Rheumatol,2010 Oct 1.
6Saag KG,Teng GG,Patkar NM,et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis Rheum,2008,59:762.
7Hyrich KL,Watson KD,Lunt M,et al.Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.Rheumatology (Oxford),2010 Jul 29.
8Kristensen LE,Kapetanovic MC,Gulfe A,et al.Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA:results from the South Swedish Arthritis Treatment Group Register.Rheumatology (Oxford),2008,47:495.
9Levalampi T,Korpela M,Vuoheenaho K,et al.Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice:adverse events and other reasons for discontinuation of treatment.Seand J Rheumatol,2008,37:6.
10Hushaw LL,Sawaqed R,Sweis G,et al.Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.Ther Clin Risk Manag,2010,6:143.
